EXAS
Price
$57.41
Change
-$2.96 (-4.90%)
Updated
Dec 18, 04:59 PM (EDT)
69 days until earnings call
NAYA
Price
$0.73
Change
-$0.07 (-8.75%)
Updated
Dec 18, 04:57 PM (EDT)
Ad is loading...

EXAS vs NAYA

Header iconEXAS vs NAYA Comparison
Open Charts EXAS vs NAYABanner chart's image
Exact Sciences
Price$57.41
Change-$2.96 (-4.90%)
Volume$31.86K
CapitalizationN/A
NAYA Biosciences
Price$0.73
Change-$0.07 (-8.75%)
Volume$300
CapitalizationN/A
EXAS vs NAYA Comparison Chart
Loading...
EXAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NAYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EXAS vs. NAYA commentary
Dec 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EXAS is a Hold and NAYA is a Hold.

COMPARISON
Comparison
Dec 19, 2024
Stock price -- (EXAS: $60.37 vs. NAYA: $0.80)
Brand notoriety: EXAS: Notable vs. NAYA: Not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: EXAS: 80% vs. NAYA: 7%
Market capitalization -- EXAS: $12.78B vs. NAYA: $2.52M
EXAS [@Medical Specialties] is valued at $12.78B. NAYA’s [@Medical Specialties] market capitalization is $2.52M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.04B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EXAS’s FA Score shows that 0 FA rating(s) are green whileNAYA’s FA Score has 0 green FA rating(s).

  • EXAS’s FA Score: 0 green, 5 red.
  • NAYA’s FA Score: 0 green, 5 red.
According to our system of comparison, NAYA is a better buy in the long-term than EXAS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EXAS’s TA Score shows that 5 TA indicator(s) are bullish while NAYA’s TA Score has 4 bullish TA indicator(s).

  • EXAS’s TA Score: 5 bullish, 4 bearish.
  • NAYA’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, EXAS is a better buy in the short-term than NAYA.

Price Growth

EXAS (@Medical Specialties) experienced а -1.96% price change this week, while NAYA (@Medical Specialties) price change was +2.55% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was -4.17%. For the same industry, the average monthly price growth was +1.60%, and the average quarterly price growth was -0.66%.

Reported Earning Dates

EXAS is expected to report earnings on Feb 25, 2025.

Industries' Descriptions

@Medical Specialties (-4.17% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
EXAS($12.8B) has a higher market cap than NAYA($2.52M). EXAS YTD gains are higher at: -18.397 vs. NAYA (-40.741). EXAS has higher annual earnings (EBITDA): 29.3M vs. NAYA (-7.69M). EXAS has more cash in the bank: 778M vs. NAYA (1.06M). NAYA has less debt than EXAS: NAYA (8.81M) vs EXAS (2.56B). EXAS has higher revenues than NAYA: EXAS (2.5B) vs NAYA (1.92M).
EXASNAYAEXAS / NAYA
Capitalization12.8B2.52M508,542%
EBITDA29.3M-7.69M-381%
Gain YTD-18.397-40.74145%
P/E RatioN/A0.05-
Revenue2.5B1.92M130,412%
Total Cash778M1.06M73,674%
Total Debt2.56B8.81M29,014%
FUNDAMENTALS RATINGS
EXAS vs NAYA: Fundamental Ratings
EXAS
NAYA
OUTLOOK RATING
1..100
6563
VALUATION
overvalued / fair valued / undervalued
1..100
42
Fair valued
49
Fair valued
PROFIT vs RISK RATING
1..100
10090
SMR RATING
1..100
91100
PRICE GROWTH RATING
1..100
4359
P/E GROWTH RATING
1..100
10046
SEASONALITY SCORE
1..100
85n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EXAS's Valuation (42) in the Biotechnology industry is in the same range as NAYA (49) in the null industry. This means that EXAS’s stock grew similarly to NAYA’s over the last 12 months.

NAYA's Profit vs Risk Rating (90) in the null industry is in the same range as EXAS (100) in the Biotechnology industry. This means that NAYA’s stock grew similarly to EXAS’s over the last 12 months.

EXAS's SMR Rating (91) in the Biotechnology industry is in the same range as NAYA (100) in the null industry. This means that EXAS’s stock grew similarly to NAYA’s over the last 12 months.

EXAS's Price Growth Rating (43) in the Biotechnology industry is in the same range as NAYA (59) in the null industry. This means that EXAS’s stock grew similarly to NAYA’s over the last 12 months.

NAYA's P/E Growth Rating (46) in the null industry is somewhat better than the same rating for EXAS (100) in the Biotechnology industry. This means that NAYA’s stock grew somewhat faster than EXAS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EXASNAYA
RSI
ODDS (%)
Bullish Trend 2 days ago
69%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
82%
Momentum
ODDS (%)
Bearish Trend 2 days ago
73%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
78%
Bullish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 20 days ago
73%
Bullish Trend 7 days ago
82%
Declines
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
75%
Bullish Trend 2 days ago
84%
Aroon
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
87%
View a ticker or compare two or three
Ad is loading...
EXAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NAYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GTLB59.140.07
+0.12%
GitLab
MREO3.40-0.05
-1.45%
Mereo BioPharma Group plc
CALX35.49-0.54
-1.50%
CALIX
RSSS4.00-0.15
-3.61%
Research Solutions
RKDA5.90-0.30
-4.84%
Arcadia Biosciences

EXAS and

Correlation & Price change

A.I.dvisor indicates that over the last year, EXAS has been loosely correlated with QGEN. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if EXAS jumps, then QGEN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EXAS
1D Price
Change %
EXAS100%
-0.63%
QGEN - EXAS
55%
Loosely correlated
-0.09%
RGEN - EXAS
55%
Loosely correlated
-1.73%
FNA - EXAS
32%
Poorly correlated
-3.54%
ATEC - EXAS
29%
Poorly correlated
+0.53%
NAOV - EXAS
29%
Poorly correlated
+5.30%
More

NAYA and

Correlation & Price change

A.I.dvisor tells us that NAYA and SSKN have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NAYA and SSKN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NAYA
1D Price
Change %
NAYA100%
-2.43%
SSKN - NAYA
25%
Poorly correlated
+1.63%
PEN - NAYA
24%
Poorly correlated
+0.13%
CSTL - NAYA
24%
Poorly correlated
-2.29%
ATR - NAYA
23%
Poorly correlated
-2.71%
EXAS - NAYA
23%
Poorly correlated
-0.63%
More